Overview

SciFluor is engaged in innovative fluorine-enabled drug discovery and development. With a singular focus and dedicated expertise in fluorine chemistry, SciFluor is strategically incorporating fluorine to improve drug profiles.

Approximately 25% of currently marketed drugs contain fluorine, including well-known products like Lipitor®, Zetia®, Januvia®, Cipro® and Prozac®.  Fluorine modification of the underlying chemical structure of a drug has been demonstrated to improve potency, selectivity, tissue penetration, half-life and metabolic stability.  SciFluor incorporates fluorine or fluorine-containing groups to synthesize new chemical entities with the potential for improved efficacy, safety and patient acceptance.  The company has created a proprietary pipeline of novel and differentiated small molecule compounds and is advancing them toward clinical testing.

Through creative and synergistic approaches to structuring business relationships, SciFluor is able to drive significant R&D value for its strategic partners. The scope of SciFluor capabilities provides companies with a range of options to greatly expand their pipeline of innovative medicine, including in-licensing or co-development of compounds in the portfolio or co-discovery of next generation new chemical entities for their proprietary therapeutic targets.

SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
read more >

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
read more >

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
read more >

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
read more >

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
read more >


Lipitor® is a registered trademark of Pfizer, Inc., Zetia® is a registered trademark of MSP Singapore Company, LLC, Januvia® is a registered trademark of Merck & Co., Inc., Cipro® is a registered trademark of Bayer Schering Pharma AG and Prozac® is a registered trademark of Eli Lilly and Company.